NCT07180576Not yet recruitingPhase 1/2
The FORCE Trial Pilot: Fish Oil-enriched Nutrition for Radiotherapy in Cancer of the hEad and Neck
The FORCE Trial Pilot
Source: ClinicalTrials.gov · Last updated 7 Aug 2026
Brief summary (registry, in English)
en-label, proof-of-concept study designed to evaluate the feasibility, safety, and acceptability of a prophylactic fish oil-enriched nutritional supplement (Fresubin Supportan) in patients with head and neck cancer (HNC) undergoing curative-intent chemoradiotherapy (CRT) at the University of Kansas Medical Center. The study involves daily supplementation starting two weeks prior to CRT and continuing throughout CRT, alongside weekly nutrition counseling.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 5 Sept 2025
- Start date
- 1 Jun 2027
- Primary completion date
- 31 May 2028
- Lead sponsor
- Anna Arthur, PhD
- Diseases
- Head and neck cancer
- NCT number
- NCT07180576
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 15
- From 1 Jun 2027 to the primary completion date, 31 May 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior head/neck RT
- Receiving therapeutic anticoagulation (e.g., warfarin, direct oral anticoagulants) and/or clotting disorders (e.g., hemophilia, thrombocytopenia)
Other illness
- Metastatic disease
- Prior cancer within 3 years (except non-melanoma skin cancer and cervical carcinoma in situ)
- Severe psychiatric illness
- Medical conditions impairing participation/adherence
- Dairy, soy, and/or fish allergy
- Documented history of atrial fibrillation or other significant arrhythmias
Other
- Presence of malnutrition at diagnosis per ASPEN criteria
- Inability to consent
- Non-adults, pregnant women, prisoners, and other legally protected vulnerable groups
- Non-English speaking
Who the study is looking for
- Newly diagnosed with Stage I - IV oral cavity, hypopharyngeal, oropharyngeal, or laryngeal cancer
- Age 18+
- Planned for definitive radiotherapy with or without surgery and chemotherapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.